Trial Outcomes & Findings for Stimulation of Cingulo-opercular Alertness Network (NCT NCT04817891)
NCT ID: NCT04817891
Last Updated: 2025-10-22
Results Overview
Score on a 4-item subscale of the 17-item Dementia Cognitive Fluctuation Scale (DCFS), developed to address limitations in prior scales and has good test-retest and inter-rater reliability; this subscale highly discriminates between dementia with Lewy bodies (DLB) and other dementia groups. The DCFS is a subjective report of cognitive fluctuation, the spontaneous change in cognitive ability which is a core diagnostic feature of DLB. Total subscale scores range from 4 to 20, with higher scores indicating greater cognitive fluctuations. A decrease in score between Baseline and Post-Testing indicates an improvement in cognitive fluctuation.
COMPLETED
NA
15 participants
Baseline and Post-Testing (3-4 weeks)
2025-10-22
Participant Flow
Participants enrolled are those who consented to be in the study. They then underwent a screening process. Three participants did not continue after the screening process.
Participant milestones
| Measure |
Experimental: HD-tDCS
HD-tDCS treatment for 20 minutes, repeated across 10 sessions (3-5 sessions/week). The pattern and dose of stimulation was individualized for each participant to generate electric field in regions of cholinergic denervation, as determined by reduced FEOBV binding. A maximum of 4 milliamps (mA) of current was delivered at each anode.
|
|---|---|
|
Overall Study
STARTED
|
15
|
|
Overall Study
Began Study Treatment
|
13
|
|
Overall Study
COMPLETED
|
12
|
|
Overall Study
NOT COMPLETED
|
3
|
Reasons for withdrawal
| Measure |
Experimental: HD-tDCS
HD-tDCS treatment for 20 minutes, repeated across 10 sessions (3-5 sessions/week). The pattern and dose of stimulation was individualized for each participant to generate electric field in regions of cholinergic denervation, as determined by reduced FEOBV binding. A maximum of 4 milliamps (mA) of current was delivered at each anode.
|
|---|---|
|
Overall Study
Did not pass screening after consenting to participate
|
1
|
|
Overall Study
Adverse Event
|
1
|
|
Overall Study
Withdrawal by Subject
|
1
|
Baseline Characteristics
Stimulation of Cingulo-opercular Alertness Network
Baseline characteristics by cohort
| Measure |
Experimental: HD-tDCS
n=13 Participants
Maximum 4 milliAmp (mA) per channel of HD-tDCS treatment for 20 minutes, for 10 sessions. Total mA dose determined by individualized computational models.
HD-tDCS: Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
|
|---|---|
|
Age, Continuous
|
75.77 years
STANDARD_DEVIATION 5.75 • n=39 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=39 Participants
|
|
Sex: Female, Male
Male
|
11 Participants
n=39 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=39 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
13 Participants
n=39 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
White
|
13 Participants
n=39 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=39 Participants
|
|
Region of Enrollment
United States
|
13 participants
n=39 Participants
|
PRIMARY outcome
Timeframe: Baseline and Post-Testing (3-4 weeks)Population: Data is reported for participants who completed both baseline and week 3/4 measures.
Score on a 4-item subscale of the 17-item Dementia Cognitive Fluctuation Scale (DCFS), developed to address limitations in prior scales and has good test-retest and inter-rater reliability; this subscale highly discriminates between dementia with Lewy bodies (DLB) and other dementia groups. The DCFS is a subjective report of cognitive fluctuation, the spontaneous change in cognitive ability which is a core diagnostic feature of DLB. Total subscale scores range from 4 to 20, with higher scores indicating greater cognitive fluctuations. A decrease in score between Baseline and Post-Testing indicates an improvement in cognitive fluctuation.
Outcome measures
| Measure |
Experimental: HD-tDCS
n=12 Participants
HD-tDCS treatment for 20 minutes, repeated across 10 sessions (3-5 sessions/week). The pattern and dose of stimulation was individualized for each participant to generate electric field in regions of cholinergic denervation, as determined by reduced FEOBV binding. A maximum of 4 milliamps (mA) of current was delivered at each anode.
|
|---|---|
|
Dementia Cognitive Fluctuations Scale
Baseline
|
11.75 score on a scale
Standard Deviation 3.31
|
|
Dementia Cognitive Fluctuations Scale
Week 3/4
|
8.33 score on a scale
Standard Deviation 1.56
|
SECONDARY outcome
Timeframe: Baseline and Post-Testing (3-4 weeks)Population: Ten participants completed resting-State fMRI at Baseline and Post-Testing. Two participants were not eligible for MRI.
Functional connectivity measures whether activity in different brain regions show similar patterns of change over time. Graph theory metrics of resting-state fMRI can characterize functional connectivity among nodes (regions) of a brain network, and well as between nodes of different brain networks. Network segregation is the difference of within-network and between-network connectivity as a proportion of within-network connectivity, such that higher numbers reflect more segregation. Given that network segregation typically decreases with normal and pathological aging, higher network segregation is generally considered cognitively beneficial. Network segregation was examined for the ventral attention network (the actual focus of stimulation based on observed cholinergic denervation) and the original cingulo-opercular network, which was predicted at the time of grant proposal (but not supported by the observed cholinergic denervation).
Outcome measures
| Measure |
Experimental: HD-tDCS
n=10 Participants
HD-tDCS treatment for 20 minutes, repeated across 10 sessions (3-5 sessions/week). The pattern and dose of stimulation was individualized for each participant to generate electric field in regions of cholinergic denervation, as determined by reduced FEOBV binding. A maximum of 4 milliamps (mA) of current was delivered at each anode.
|
|---|---|
|
Resting State fMRI
Baseline - Ventral Attention Network
|
0.23 ratio of network segregation
Standard Deviation 0.17
|
|
Resting State fMRI
3/4 weeks - Ventral Attention Network
|
0.33 ratio of network segregation
Standard Deviation 0.10
|
|
Resting State fMRI
Baseline - Cingulo-opercular network
|
0.53 ratio of network segregation
Standard Deviation 0.11
|
|
Resting State fMRI
3/4 weeks - Cingulo-opercular network
|
0.53 ratio of network segregation
Standard Deviation 0.11
|
SECONDARY outcome
Timeframe: Baseline, 3-4 weeksPopulation: 8 participants completed the Color Word Interference Test at Baseline and Post-Testing. 4 participants did not complete the test. Negative scores are technically possible, but given the known robust and reliable cognitive effort required in color word interference, a negative interference score would call into question the validity of the administration and be excluded. No participants' scores were negative and therefore none were excluded for this reason..
Outcome Measure Description: Interference score in time to complete the Color Word Interference Test version of the Stroop task from the Delis-Kaplan Executive Function System. Participants 1) identify a series of colors, 2) read color words (e.g. blue) all written in black ink, and 3) name the ink color of color words printed in incongruous colored inks (e.g. for the word "green" written in red ink, the correct response is "red"). Tasks are performed as quickly as possible. Time to complete each task is recorded. Interference score is calculated as the time to complete the color-word (interference) test (CWT), less the average of the time to complete the color task (CT) and word-reading task (WT): CWT - ((CT + WT)/2). The score has a theoretical valid range of 0 - 300; a lower score suggests better cognitive control. A negative change (decrease) in score between Baseline and Post-Testing indicates improvement in cognitive control performance.
Outcome measures
| Measure |
Experimental: HD-tDCS
n=8 Participants
HD-tDCS treatment for 20 minutes, repeated across 10 sessions (3-5 sessions/week). The pattern and dose of stimulation was individualized for each participant to generate electric field in regions of cholinergic denervation, as determined by reduced FEOBV binding. A maximum of 4 milliamps (mA) of current was delivered at each anode.
|
|---|---|
|
Stroop Color Word Interference Test - Cognitive Control Performance
Baseline
|
143.44 calculated score
Standard Deviation 51.89
|
|
Stroop Color Word Interference Test - Cognitive Control Performance
3-4 weeks
|
125.15 calculated score
Standard Deviation 52.91
|
SECONDARY outcome
Timeframe: Baseline, 3-4 weeksPopulation: 12 participants completed the n-back working memory task at both Baseline and Post-Testing, however one participant used an incorrect button to make responses at Baseline, so these responses were not recorded, leaving 11 participants with recorded data at Baseline and Post-Testing. Of these 11, 5 performed below chance (\<50% hit rate) on the control task at one or both timepoints and were excluded from analysis.
The n-back test is a working memory task where a participant identify a stimulus that matches the stimulus experienced "n" steps back. Participants performed a 2-back test, in which they were asked to remember and press a button when presented with a stimulus that appeared two steps before the current one (e.g. square, circle, square). The number of correct and incorrect identifications are normalized (z-score). Total score is the z-score of correct button presses minus the z-score of incorrect button presses. Possible scores range from -4.85 to 4.85. A higher score (d') reflects better discrimination between target and non-target stimuli, and therefore better working memory performance. A positive change (increase) in 2-back score (d') between Baseline and Post-Testing indicates an improvement in working memory performance.
Outcome measures
| Measure |
Experimental: HD-tDCS
n=6 Participants
HD-tDCS treatment for 20 minutes, repeated across 10 sessions (3-5 sessions/week). The pattern and dose of stimulation was individualized for each participant to generate electric field in regions of cholinergic denervation, as determined by reduced FEOBV binding. A maximum of 4 milliamps (mA) of current was delivered at each anode.
|
|---|---|
|
Objective Measures of Working Memory (N-back Test)
Baseline
|
0.94 calculated score
Standard Deviation 0.72
|
|
Objective Measures of Working Memory (N-back Test)
3-4 weeks
|
1.24 calculated score
Standard Deviation 0.60
|
Adverse Events
Experimental: HD-tDCS
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Experimental: HD-tDCS
n=13 participants at risk
Maximum 4 milliAmp (mA) per channel of HD-tDCS treatment for 20 minutes, for 10 sessions. Total mA dose determined by individualized computational models.
HD-tDCS: Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
|
|---|---|
|
Nervous system disorders
Progression of preexisting delusions related to Lewy Body Dementia disease progression
|
7.7%
1/13 • 4 weeks
|
|
Skin and subcutaneous tissue disorders
Itching
|
53.8%
7/13 • 4 weeks
|
|
General disorders
Worsening of dizziness upon standing post treatment
|
7.7%
1/13 • 4 weeks
|
|
Skin and subcutaneous tissue disorders
Burning sensation
|
100.0%
13/13 • 4 weeks
|
|
General disorders
Tingling
|
100.0%
13/13 • 4 weeks
|
|
Skin and subcutaneous tissue disorders
Scalp Pain
|
53.8%
7/13 • 4 weeks
|
|
General disorders
Trouble Concentrating
|
38.5%
5/13 • 4 weeks
|
|
General disorders
Sleepiness
|
61.5%
8/13 • 4 weeks
|
|
General disorders
Headache
|
23.1%
3/13 • 4 weeks
|
|
General disorders
Acute Mood Change
|
15.4%
2/13 • 4 weeks
|
|
Musculoskeletal and connective tissue disorders
Neck Pain
|
7.7%
1/13 • 4 weeks
|
|
Skin and subcutaneous tissue disorders
Skin Redness
|
76.9%
10/13 • 4 weeks
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place